Trials / Enrolling By Invitation
Enrolling By InvitationNCT06992687
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0052 in Patients With Advanced Solid Tumors
- Status
- Enrolling By Invitation
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors
Detailed description
To determine the maximum tolerated dose (MTD) or dose-limiting toxicity（DLT）or optimal biological dose (OBD) and/or the recommended Phase 2 doses (RP2Ds) for HB0052.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HB0052 Injection | An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2025-09-30
- Completion
- 2025-11-30
- First posted
- 2025-05-28
- Last updated
- 2025-05-28
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06992687. Inclusion in this directory is not an endorsement.